Key result
Hemospray application linked to 100% initial hemostasis in active lower GI bleeding.
Why the study?
The feasibility and effectiveness of Hemospray for acute lower gastrointestinal bleeding in a wider range of conditions were not well defined.
Does Hemospray achieve hemostasis in patients with active lower gastrointestinal bleeding?
Observational (n=9)
Yes
Does Hemospray achieve hemostasis in patients with active lower gastrointestinal bleeding?
Hemospray is effective for achieving initial hemostasis in active lower gastrointestinal bleeding, though caution is advised for patients on antithrombotic therapy or with spurting bleeds.
May support initial hemostasis in lower GI bleeding; leaves open durability and generalizability in prospective trials.
Acute lower gastrointestinal bleeding (LGIB) is diverse in origin and can be substantial, requiring urgent hemostasis. Hemospray is a promising novel hemostatic agent for upper gastrointestinal bleeding (UGIB). It has been claimed in a small series that the use of Hemospray is also feasible in LGIB. We aimed to expand our knowledge of the application of Hemospray for the treatment of LGIB in a wider range of conditions to further define the optimal patient population for this new therapeutic modality. We analyzed the outcomes of nine unselected consecutive patients with active LGIB treated with Hemospray in two major hospitals in Europe. Initial hemostasis was achieved after Hemospray application in all patients. Rebleeding occurred in two patients (22%) who were on acetyl salicylic acid and presented with spurting bleeds. These preliminary data show that Hemospray can be effective in the management of LGIB, but suggest cautious use for patients on antithrombotic therapy and spurting bleeds.
No takes yet. Share an insight, caveat, or question.
Holster et al. (2013) conducted an observational in Acute lower gastrointestinal bleeding (LGIB) (n=9). Hemospray was evaluated on Initial hemostasis. Hemospray application achieved initial hemostasis in 100% of patients with active lower gastrointestinal bleeding, with a 22% rebleeding rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: